Literature DB >> 21204770

A case of rituximab-induced hepatitis.

Christopher Joseph Del Prete1, Neil S Cohen.   

Abstract

A case of hepatitis in a patient receiving rituximab for ITP is reported. After an extensive workup, no infectious or autoimmune etiology could be found. The authors believe that this represents a case of drug-induced hepatitis, which has not been reported for this agent in the past.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21204770     DOI： 10.1089/cbr.2010.0806

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN： 1084-9785            Impact factor:   3.099


  4 in total

1.  Rituximab-induced autoimmune hepatitis: A case study and literature review.

Authors:  Polymnia Galiatsatos; Sarit Assouline; Adrian Gologan; Nir Hilzenrat
Journal:  Can Liver J       Date:  2020-11-17

2.  Rituximab-related reversible hepatocellular damage.

Authors:  Selami K Toprak; Sema Karakuş
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

3.  DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.

Authors:  Yutaka Shimazu; Masaharu Nohgawa
Journal:  J Clin Exp Hematop       Date:  2019

4.  Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments.

Authors:  Joerg Latus; Reinhild Klein; Ina Koetter; Matthias Schwab; Peter Fritz; Martin Kimmel; M Dominik Alscher; Niko Braun
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.